Fernandez J, Montaudié H, Courdi A, Georgiou C, Camuzard O, Chignon-Sicard B
Service de chirurgie plastique, réparatrice et esthétique, hôpital Saint-Roch, CHU de Nice, 5, rue Pierre-Dévoluy, 06000 Nice, France.
Service de dermatologie, hôpital de l'Archet 2, CHU de Nice, 151, route de Saint-Antoine, 06200 Nice, France.
Ann Chir Plast Esthet. 2016 Feb;61(1):69-75. doi: 10.1016/j.anplas.2014.09.013. Epub 2014 Oct 28.
This article describes the unique case of a female patient who presented distant melanoma metastasis on the breast while having irradiation therapy for breast cancer. This happened eight months after the initial treatment for a melanoma of the back (under the right scapula). Furthermore, this case report demonstrates the efficiency of Vemurafenib® as a treatment for late stage melanomas.
The patient was a 47-year-old female that had a superficial spreading melanoma under the right scapula (Breslow 1.02mm) that was treated with 2cm skin excision and sentinel lymph node sampling that was negative. The melanoma was positive for the BRAF600E mutation. One month after this incident, the patient developed breast cancer that was treated with conservative surgery and radiotherapy. Three months after the end of the irradiation treatment, she developed multiple melanoma metastasis on the skin of the breast. Our multidisciplinary team decided to initiate a treatment with vemurafenib. The patient showed an excellent response, so the surgical team completed the treatment with a radical mastectomy and immediate reconstruction with a pedicled latissimus dorsi flap. The histologic report of the mastectomy specimen showed no sign of melanocytic proliferation, that demonstrates the efficacy of vemurafenib. The patient showed no relapse after two years of follow-up.
The speed of development and location of cutaneous metastases in this case brought us to think about the effects of radiation therapy on the skin. Radiation therapy causes acute complications (radiodermatitis) by cellular and molecular mechanisms. Moreover, depressed immunity is found after irradiation. Association of these mecanisms could explain the appearance of these metastases in irradiation field. The efficiency of vemurafenib found in our case is consistent with what is described in literature, especially with the improvement in median overall survival.
This case demonstrates a unique case of distant melanoma metastasis on the irradiation field of a breast cancer. It also demonstrates the efficacy of vemurafenib as well as the efficacy of a radical complementary surgical treatment in these patients.
本文描述了一名女性患者的独特病例,该患者在接受乳腺癌放射治疗时出现了远处黑色素瘤转移至乳房的情况。这发生在最初治疗背部(右肩胛骨下方)黑色素瘤八个月后。此外,本病例报告展示了维莫非尼(Vemurafenib®)治疗晚期黑色素瘤的有效性。
患者为一名47岁女性,右肩胛骨下方有浅表扩散性黑色素瘤(Breslow厚度1.02mm),接受了2cm皮肤切除术及前哨淋巴结取样,结果为阴性。该黑色素瘤BRAF600E突变呈阳性。此次事件一个月后,患者患上乳腺癌,接受了保守手术和放疗。放疗结束三个月后,她在乳房皮肤出现多处黑色素瘤转移。我们的多学科团队决定开始使用维莫非尼进行治疗。患者反应良好,因此手术团队通过根治性乳房切除术和带蒂背阔肌皮瓣即刻重建完成了治疗。乳房切除标本的组织学报告显示无黑素细胞增殖迹象,这证明了维莫非尼的疗效。随访两年后患者未出现复发。
该病例中皮肤转移灶的发展速度和位置促使我们思考放射治疗对皮肤的影响。放射治疗通过细胞和分子机制引发急性并发症(放射性皮炎)。此外,放疗后发现免疫力下降。这些机制的关联可以解释这些转移灶在放疗区域的出现。我们病例中发现的维莫非尼的有效性与文献中描述的一致,尤其是中位总生存期的改善。
本病例展示了乳腺癌放疗区域远处黑色素瘤转移的独特病例。它还证明了维莫非尼的有效性以及根治性辅助手术治疗对这些患者的有效性。